Published online before print October 21, 2004, doi: 10.1161/01.ATV.0000148322.89911.44
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults
The CARDIA Study
From the Division of Research (C.I., J.A.D., S.S.), Kaiser Permanente, Oakland, Calif; the Department of Laboratory Medicine and Pathology (M.D.G.), School of Medicine, University of Minnesota, Minneapolis; the Division of Epidemiology (M.D.G., D.R.J.), School of Public Health, University of Minnesota, Minneapolis; the Institute for Nutrition Research (D.R.J.), University of Oslo, Oslo, Norway; and National Institutes of Health/National Heart, Lung, and Blood Institute/Division of Epidemiology and Clinical Applications (C.M.L.), Epidemiology and Biometry Program, Bethesda, Md.
Correspondence to Carlos Iribarren, MD, MPH, PhD, Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA. E-mail cgi{at}dor.kaiser.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— To examine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with calcified coronary plaque in young adults.
Methods and Results— Nested case-control study among CARDIA participants at the year 15 examination (2000 to 2001, 33 to 45 years old). Cases (n=266) were those with and controls (n=266) those without evidence of calcified coronary plaque by computed tomography matched 1:1 on sex and race. Lp-PLA2 mass and activity were significantly higher in cases (296±101 ng/mL and 36.4±12.3 nmol/mL per minute) than in controls (267±80 ng/mL and 32.9±11.8 nmol/mL per minute). In age-adjusted conditional logistic regression, the odds ratio (OR) of calcified coronary plaque per 1 standard deviation (SD) increment was 1.40 (95% CI, 1.17 to 1.67) and 1.39 (95% CI, 1.14 to 1.70) for Lp-PLA2 mass and activity, respectively. After adjusting for multiple covariates including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and C-reactive protein, a statistically significant association remained for Lp-PLA2 mass (OR, 1.28; 95% CI, 1.03 to 1.60) but not for activity (OR, 1.09; 95% CI, 0.84 to 1.42). No evidence was found for interaction between Lp-PLA2 mass or activity with LDL-C as predictors of calcified coronary plaque.
Conclusion— An independent association of Lp-PLA2 mass with calcified coronary plaque existed in young adults. Therefore, Lp-PLA2 mass may be a useful marker of subclinical cardiovascular risk.
This nested case-control study among CARDIA participants at the year 15 examination (2000 to 01, 33 to 45 years old) demonstrates an independent association of Lp-PLA2 mass (but not its activity) with presence and amount of calcified coronary plaque. Therefore, Lp-PLA2 mass may be a useful marker of sub-clinical cardiovascular risk.
Key Words: phospholipases • coronary calcification • young adults • atherosclerosis • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Lipoprotein-associated phospholipase A2 (Lp-PLA2, also termed as platelet-activating factor acetylhydrolase [PAF-AH]) is a 441-amino acid calcium-independent enzyme synthesized by macrophages and platelets that exists in 2 forms: intracellular and circulating in plasma, 80% bound to LDL particles.1–3 Lp-PLA2 hydrolyzes oxidized phospholipids generating chemotactic/pro-atherogenic byproducts (lysophosphatidylcholine and oxidized fatty acids).3 Additionally, it inactivates platelet-activating factor and thus may also be anti-inflammatory/antithrombotic.4
Three epidemiological studies have been published focusing on Lp-PLA2 mass, and the results are not entirely consistent. In the West of Scotland Coronary Prevention Study, Lp-PLA2 mass had a strong, positive association with risk of major coronary events, independently of cardiovascular disease risk factors.5 In the Women’s Health Study, the association between Lp-PLA2 mass and all cardiovascular disease was markedly attenuated and became nonstatistically significant after risk factor adjustment.6 In the ARIC Study, Lp-PLA2 mass independently predicted risk of incident coronary heart disease among individuals below median LDL cholesterol (LDL-C <130 mg/dL).7
Lp-PLA2 or PAF-AH activity has been examined in the context of multiple inflammatory pathologies. Whereas Lp-PLA2 activity may be upregulated as part of the acute phase response,8–10 it may be downregulated in the context of different disease states or therapies.11–16 In the AtheroGene study, individuals within the highest quartile of PAF-AH activity had a 1.8-fold increase in coronary artery disease (CAD) risk (95% CI, 1.01 to 3.2) compared with those in the first quartile and after adjusting for clinical and metabolic factors.17
The aims of this investigation were to describe the demographic, lifestyle, and biochemical correlates of Lp-PLA2 mass and activity in a sample of white and black young adults and to characterize the association of Lp-PLA2 mass and activity with the presence of calcified coronary plaque ascertained by cardiac computed tomography (CT).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The Coronary Artery Risk Development in Young Adults (CARDIA) study is an ongoing investigation of heart disease risk factors and subclinical CAD among black and white men and women aged 18 through 30 years at study inception in 1985 to 1986. More details of study design, recruitment, and procedures have been published elsewhere.18,19 Participants were recruited in 4 field centers: Birmingham, Ala; Chicago, Ill; Minneapolis, Minn; and Oakland, Calif.
A nested case-control study design was used with data collected at the CARDIA Year 15 examination (June 2000 to October 2001), in which the participants were between the ages of 33 and 45. Cases (n=266) were all study participants who had evidence of calcified coronary plaque (ie, coronary calcium score >0), and controls were members with a calcium score of zero individually matched to cases based on sex and race. Of the original 282 cases, 16 were excluded in the final analysis for missing data on covariates of interest.
Age, race/ethnicity, and educational attainment were ascertained by self-report. Alcohol and tobacco use were ascertained by self-report and by interviewer-administered questionnaire if the participant reported ever drinking or smoking.20 Blood samples were drawn after an overnight fast. The protocols for lipid determination can be found elsewhere.21–23 Anthropometric measures (weight, height, waist and hip girths) were performed according to the CARDIA study protocol.24 Body mass index was calculated as weight/height2 (kg/m2). Fasting plasma glucose was determined at Linco Research Inc using the hexokinase–ultraviolet method.25 C-reactive protein (CRP) was measured with an ultrasensitive enzyme-linked immunosorbent assay based on purified protein and polyclonal anti-CRP antibodies (Calbiochem).26 Hypertension was defined as self-report of hypertension and/or systolic blood pressure 
140 mm Hg and diastolic blood pressure 90 mm Hg and/or use of antihypertensive medication. Diabetes was defined as self-report of diabetes mellitus and/or fasting blood glucose 126 mg/dL and/or use of antidiabetic medication. Hormone replacement therapy and use of cholesterol lowering medication were ascertained by self-report. The institutional review boards of the field centers approved the study, and all participants gave informed written consent.
Measurement of Lp-PLA2 Mass and Activity
Lp-PLA2 mass was measured using a 2-site enzyme-linked immunoabsorbent assay (diaDexus Inc, South San Francisco, Calif) on serum samples stored at –70°C for an average of 18 months.27 The highest standard in the assay is 1000 ng/mL and the lowest limit of detection is 1 ng/mL. The interassay coefficient of variation was 20%. The correlation between split Lp-PLA2 mass measurements in 119 randomly selected samples was 0.91.
Lp-PLA2 activity was measured at the Molecular Epidemiology and Biomarker Research Laboratory (University of Minnesota, Minneapolis) using a method described by Stafforini et al28 with slight modifications. We used Sep-Pak Plus C18 cartridges from Waters instead of Kaker Chemical Co, and our units are reported as nmol/mL per minute instead of µmol/mL per hour. The substrate for this analysis was obtained from Avanti Polar Lipids part number 840009. The interassay coefficient of variation was 9%, and in 294 split sample pairs the correlation was 0.76.
CT Scanning Protocol
Two scans were obtained on each participant, 1 to 2 minutes apart. Participants were scanned in supine position (without getting off the table between scans) over a hydroxy-apatite phantom to adjust for scanner and participant differences in CT attenuation numbers (ie, Hounsfield units) across field centers. The Chicago and Oakland field centers used Imatron C-150 scanners, the Birmingham field center used a GE Lightspeed Qxi scanner, and the Minneapolis field center used a Siemens VZ scanner. An experienced and trained CT image analyst (blinded to nonscan data and to the order of images) identified the courses of the coronary arteries using specially developed image-processing software and calculated an Agatston score modified to account for slice width and adjusted to standardized CT attentuations values based on the calibration phantom, which was imaged with each participant.29 Additional details of the phantom calibration and CT protocol can be found in our previous publications.30,31 In the analysis, we used the mean of the 2 readings. There were 2921 (96.5%) concordant positive (score >0) or concordant negative (score=0) scans and 107 (3.5%) discordant scans (ie, one zero scan and one nonzero scan). Of the discordant scans, 9 (8%), 33 (31%), 4 (4%), 56 (%), and 5 (5%) were adjudicated to definitely negative, probably negative, cannot tell, probably positive, and definitely positive, respectively. For the first 3 categories, the adjudicated score was set to zero; for the last 2 categories, the adjudicated score was set to the score of the positive scan. A second expert reader who was not from the Reading Center trained in the software usage reviewed 100 discordant scan pairs using the same adjudication process. The agreement was 91%.
Statistical Analysis
Univariate case-control differences were ascertained using the t test for normally distributed continuous variables, the Wilcoxon rank-sum test for continuous variables that were not normally distributed (alcohol intake, triglycerides and CRP), and the 
2 test for categorical variables. To assess bivariate associations of Lp-PLA2 mass and activity with other covariates, we computed means and SD (or proportions) of the covariates according to sex-/race-specific tertiles of Lp-PLA2 mass and activity, respectively. Tests for linear trend were estimated using the significance of Pearson correlation coefficients for continuous variables and the Cochran–Armitage test for 2 by n categorical variables. Heterogeneity of means across groups was assessed with analysis of variance (ANOVA). Conditional logistic regression was then applied to quantify the relative odds of calcified coronary plaque (ie, calcium score >0 versus calcium score=0) associated with 1 (sex- and race-specific) SD linear increment in Lp-PLA2 mass and activity, respectively. We also implemented conditional logistic models with Lp-PLA2 mass and activity entered as [sex- and race-specific] tertiles 2, 3 with tertile 1 as the reference group. Both the SD and the tertile cutpoints were estimated among controls. Because of the high correlation between mass and activity, we performed separate models for mass and activity. Three sequential models were fitted: model 1, adjusting for age only (sex and race are adjusted for by design); model 2, adjusting for (in addition to age) education attainment, alcohol consumption, cigarette smoking, body mass index, waist circumference, diabetes and hypertension; model 3, further adjusting for LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides; and model 4, further adjusting for CRP. We also considered a variation of model 3 that included only LDL-C.
Because of previous epidemiological evidence indicating a stronger association of Lp-PLA2 mass among individuals with low LDL-C,7 we tested the significance (in fully adjusted models) of interactions of Lp-PLA2 mass and activity with LDL-C as predictors of calcified coronary plaque. Because none of the interactions was statistically significant (P for interaction between Lp-PLA2 mass and LDL-C=0.52; P for interaction between Lp-PLA2 activity and LDL-C=0.68), we did not perform stratified analyses by LDL-C level. The SAS software, version 8 (SAS Institute), was used in all statistical analyses.
To examine whether there is a quantitative relationship between Lp-PLA2 mass and activity and coronary artery calcium (not just presence or absence of calcified coronary plaque), we used an alternative analytical approach consisting of linear regression models with log (calcium score +1) as the dependent variable, Lp-PLA2 mass, and activity as continuous predictors and the same covariate adjustment sequence (ie, models 1 through 4). This strategy has proven to detect associations with cardiovascular risk factors in previous studies.32
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Compared with controls, cases tended to be slightly older (by 1.5 years) and had lower educational attainment (Table 1). Cases were significantly more likely to be current smokers, to have a history of hypertension, and to be using cholesterol-lowering medication. Although diabetes was twice as common in cases as in controls, this difference did not reach statistical significance. Hormone replacement therapy was very rare in our sample (<3%) and did not differ by case-control status. Waist circumference, LDL-C, and triglycerides were significantly higher, whereas HDL-C was significantly lower in cases compared with controls. Both Lp-PLA2 mass and activity were significantly higher in cases than in controls. However, no statistically significant differences were found for alcohol intake, body mass index, and CRP level between cases and controls. Among the cases, the average (±SD) calcium score was 85 (± 272); approximately half of the cases had a calcium score <20 and 32% had a calcium score of
50. In descriptive analysis combining cases and controls (Figure 1), Lp-PLA2 mass was highest in white men, followed by white women, black men, and black women (P ANOVA <0.0001). In turn, Lp-PLA2 activity was highest in white men, followed by black men, white women, and black women (P ANOVA <0.0001).
|
|
Means of waist circumference, LDL-C, and triglycerides increased and HDL-C decreased linearly with the levels of both Lp-PLA2 mass and activity (Table 2). There were also significant positive linear trends of age and educational attainment across levels of Lp-PLA2 activity. There were no discernible trends with all the other covariates. The Pearson linear correlation between Lp-PLA2 mass and activity was 0.61; Lp-PLA2 mass correlated 0.39 with LDL-C and –0.25 with HDL-C; Lp-PLA2 activity correlated 0.52 with LDL-C and –0.33 with HDL-C. The Spearman rank-order correlation with triglycerides was 0.11 for mass and 0.33 for activity.
|
The proportion of cases with calcified coronary plaque increased in a stepwise fashion with tertiles of both Lp-PLA2 mass and activity in both men and women (Figure 2).
|
In age-adjusted conditional logistic regression (model 1), Lp-PLA2 mass and activity were significantly associated with calcified coronary plaque (odds ratio [OR] per 1 standard deviation [SD] increment=1.40; 95% CI, 1.17 to 1.67 for mass; OR, 1.39; 95% CI, 1.14 to 1.70 for activity) (Table 3). Age-adjusted OR for the upper tertile, relative to the lowest tertile, were 2.15 (95% CI, 1.36 to 3.42) for mass and 2.40 (95% CI, 1.52 to 3.81) for activity. After adjusting for age, educational attainment, smoking status, alcohol consumption, body mass index, waist circumference, diabetes, and hypertension (model 2), the risk relations did not change appreciably. Further adjustment for LDL-C, HDL-C, and triglycerides (model 3) resulted in attenuation of the strength of the associations but, whereas Lp-PLA2 mass remained significantly related, Lp-PLA2 activity was no longer significantly related to calcified coronary plaque. In a variation of model 3 with entry of LDL-C alone (in addition to model 2 covariates), the OR associated with 1 SD increment of Lp-PLA2 mass was 1.29 (95% CI, 1.04 to 1.60), and the OR associated with 1 SD increment of Lp-PLA2 activity was 1.18 (95% CI, 0.91 to 1.52). Further adjustment for CRP (Model 4) did not change the results.
|
In the linear model of log (calcium score +1), the slope estimates associated with 1 SD increment (standard error; P) were as follows (first value is for Lp-PLA2 mass, second is for Lp-PLA2 activity): 0.25 (0.07; 0.0006) and 0.26 (0.08; 0.002) after adjustment for age, sex, and race (the inclusion of sex and race in model 1 is necessary because the linear model is not matched); 0.22 (0.07; 0.003) and 0.22 (0.08; 0.007) in model 2; 0.15 (0.08; 0.06) and 0.11 (0.10; 0.27) in model 3; and 0.15 (0.08; 0.05) and 0.11 (0.09; 0.28) in model 4.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study documents, for the first time to our knowledge in young adults, an independent association of Lp-PLA2 mass with presence of calcified coronary plaque and amount of coronary calcium and thus supports the notion that Lp-PLA2 may be relevant to atherogenesis. In this regard, recent evidence indicates that Lp-PLA2 has great affinity for small, dense LDL particles, known to be more susceptible to oxidative modification and to be atherogenic,33 and that Lp-PLA2 byproducts may be involved in apoptosis of macrophages and smooth muscle cells, a process that can lead to atherosclerosis progression.34
Our findings confirm and extend earlier results of the West of Scotland Coronary Prevention Study, in which Lp-PLA2 mass was a strong, independent predictor of coronary events.5 After adjustment for age, systolic blood pressure, plasma triglycerides, LDL-C, HDL-C, fibrinogen, white cell count, and CRP, an increase of 1 SD in Lp-PLA2 mass was associated, in Scottish men, with 1.18 increased hazard of coronary events (95% CI, 1.05 to 1.33). Our estimate of the risk relation with calcified coronary plaque, using a slightly different group of covariates, was 1.28 (95% CI, 1.03 to 1.60). Furthermore, in the current analysis, the OR associated with the highest tertile of Lp-PLA2 mass (2.2) was of similar magnitude to the multivariate OR observed for diabetes (2.6), hypertension (2.2), or current smoking (2.2).
An association was also found between Lp-PLA2 activity and calcified coronary plaque, but this relationship dropped below the threshold for statistical significance after adjustment for lipids, particularly LDL-C. We believe that the reason behind this attenuation is the stronger correlation between enzymatic activity and LDL-C (r=0.52) than between enzymatic mass with LDL-C (r=0.39). It could be argued that adjustment for LDL-C may be inappropriate in this case because Lp-PLA2 may be in the causal pathway connecting LDL oxidation with atherosclerosis, creating statistical colinearity.
Lp-PLA2 mass and activity differed significantly by sex–race groups, being highest in white men and lowest in black women. In agreement with the data from Packard et al,5 Lp-PLA2 mass and CRP were uncorrelated, suggesting that Lp-PLA2 and CRP represent different metabolic pathways.
The calcification of atheroma occurs early in plaque development as part of the inflammatory pathophysiologic cascade of CAD, and is actively regulated like bone mineralization.35 Although its value in cardiovascular risk stratification is not definitely established, coronary artery calcification may be an independent predictor of angiographic CAD36 and of coronary events.37–39
In our study, CRP was not associated with presence of calcified coronary plaque, a finding that is in agreement with 2 recent studies using coronary calcium scores as the outcome.40–42 It has been argued that CRP may measure the degree of plaque destabilization and ongoing ulceration or thrombosis rather than atherosclerotic mass.43
The strengths of our study include being a population-based, bi-ethnic sample, the lack of interference of treatments (only 29 participants were using cholesterol agents and 4 women were using hormone replacement therapy), and the availability of multiple established cardiac risk factors. The main limitations are the observational and cross-sectional nature of the data (precluding causal inference) and the fact that we have not characterized the CARDIA cohort for known genetic polymorphisms in the PAF-AH gene. A G994–>T missense mutation in exon 9, shown to be present in 4% of Japanese men, has been shown to be associated with reduced Lp-PLA2 activity and with increased risk of CAD.44 Further research is needed to reconcile these findings in Japanese men with the findings reported here that increased mass and activity are associated with calcified coronary plaque.
In conclusion, Lp-PLA2 mass (but not its activity) was independently associated with calcified coronary plaque among young adults. Additional studies are warranted to elucidate the contributions of Lp-PLA2 bioproducts on the risk of atherothrombosis and the value of selective inhibitors of Lp-PLA2 activity in combating atherosclerosis.
|
Acknowledgments |
|---|
This work was supported by a grant from GlaxoSmithKline to Dr Iribarren and by the National Heart, Lung, and Blood Institute of the United States (YALTA: NIH 1RO1-HL53560-01A1 and CARDIA: NO1-HC-48047 through 48050). At no time did GlaxoSmithKline have control of the data generated from this study. The authors thank Gail Husson, MPH, Med, for assistance in data analysis.
Received February 26, 2004; accepted October 11, 2004.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis AJ, Berliner JA. Role of group II secretory phospholipase A2 in atherosclerosis. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999; 19: 1291–1298.
2. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol. 1997; 17: 2257–2263.
3. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999; 338: 479–487.
4. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995; 374: 549–553.[CrossRef][Medline] [Order article via Infotrieve]
5. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD for the West of Scotland Coronary Prevention Study Group. Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease. N Engl J Med. 2000; 343: 1148–1155.
6. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001; 38: 1302–1306.
7. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Circulation. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004; 109: 837–842.
8. Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta. 2000; 1488: 102–123.[Medline] [Order article via Infotrieve]
9. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997; 272: 17895–17898.
10. Peplow PV. Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. Prostaglandins Leukot Essent Fatty Acids. 1999; 61: 65–82.[CrossRef][Medline] [Order article via Infotrieve]
11. Triggiani M, De Marino V, Sofia M, Faraone S, Ambrosio G, Carratu L, Marone G. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med. 1997; 156: 94–100.
12. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990; 91: 244–256.[Medline] [Order article via Infotrieve]
13. Kald B, Smedh K, Olaison G, Sjodahl R, Tagesson C. Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn’s disease. Digestion. 1996; 57: 472–477.[Medline] [Order article via Infotrieve]
14. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997; 38: 2281–2288.[Abstract]
15. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res. 2003; 44: 927–934.
16. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002; 22: 306–311.
17. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003; 44: 1381–1386.
18. Hughes GH, Cutter G, Donahue R, Friedman GD, Hulley S, Hunkeler E, Jacobs DR Jr., Liu K, Orden S, Pirie P. Recruitment in the Coronary Artery Disease Risk Development in Young Adults (CARDIA) Study. Controlled Clinical Trials. 1987; 8: 68S–73S.[CrossRef][Medline] [Order article via Infotrieve]
19. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr., Liu K, Savage PJ. CARDIA: Study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988; 41: 1105–1116.[CrossRef][Medline] [Order article via Infotrieve]
20. Dyer AR, Cutter GR, Liu KQ, Armstrong MA, Friedman GD, Hughes GH, Dolce JJ, Raczynski J, Burke G, Manolio T. Alcohol intake and blood pressure in young adults: the CARDIA Study. J Clin Epidemiol. 1990; 43: 1–13.[CrossRef][Medline] [Order article via Infotrieve]
21. Warnick, GR. Enzymatic Methods for Quantification of Lipoprotein Lipids. In: Albers JJ, Segrest JP, eds. Methods of Enzymology, vol 129:101B122. New York: Academic Press, Inc; 1986.
22. Warnick GR, Benderson JM, Albers JJ, Baillie EE, Sexton B, Schaefer EJ, Carlson D, Hill M, Brewer HB, Wiebe DA, Hazlehurst J, Cooper GR. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982; 28: 1379–1388.
23. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502.[Abstract]
24. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, Hulley SB, Jacobs DR Jr., Liu K, Manolio TA. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials. 1991; 12: 1S–77S[CrossRef][Medline] [Order article via Infotrieve]
25. Slein MW, Cori GT, Cori CF. A comparative study of hexokinase from yeast and animal tissues. J Biol Chem. 1950; 186: 763–780.
26. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997; 43: 52–58.
27. Dada N, Kim NW, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002; 2: 17–22.[CrossRef][Medline] [Order article via Infotrieve]
28. Stafforini DM, McIntyre TM, Prescott SM. Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol. 1990; 187: 344–357.[Medline] [Order article via Infotrieve]
29. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832.[Abstract]
30. Carr JJ, Nelson JC, Wong ND, McNitt-Gray MF, Arad Y, Jacobs DR, Sidney S, Bild DE, Williams OD, Detrano R. Measuring calcified coronary plaque with cardiac CT in population-based studies: the standardized protocol of the Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA). Radiology. In press
31. Nelson JC, Kronmal RA, Carr JJ, McNitt-Gray MF, Wong ND, Loria C, Goldin JP, Williams OD, Detrano R. Computed Tomography Coronary Calcium Measures from Images Adjusted for Attenuation Differences. Radiology. In press.
32. Reilly MP, Wolfe ML, Localio AR, Rader DJ. Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis. 2004; 173: 69–78.[CrossRef][Medline] [Order article via Infotrieve]
33. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995; 15: 1764–1773.
34. Carpenter KL, Challis IR, Arends MJ. Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPAR
. FEBS Lett. 2003; 553: 145–150.[CrossRef][Medline]
[Order article via Infotrieve]
35. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the Am Heart Association. Writing Group Circulation. 1996; 94: 1175–1192.
36. Kennedy J, Shavelle R, Wang S, Budoff M, Detrano RC. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J. 1998; 135: 696–702.[CrossRef][Medline] [Order article via Infotrieve]
37. Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R. Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. Circulation. 1997; 96: 1122–1129.
38. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, Chomka EV, Liu K. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003; 107: 2571–2576.
39. Cheng YJ, Church TS, Kimball TE, Nichaman MZ, Levine BD, McGuire DK, Blair SN. Comparison of coronary artery calcium detected by electron beam tomography in patients with to those without symptomatic coronary heart disease. Am J Cardiol. 2003; 92: 498–503.[CrossRef][Medline] [Order article via Infotrieve]
40. Hunt ME, O’Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J. 2001; 141: 206–210.[CrossRef][Medline] [Order article via Infotrieve]
41. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol. 2000; 36: 39–43.
42. Reilly MP, Wolfe ML, Localio AR, Rader DJ. Study of Inherited Risk of Coronary Atherosclerosis. C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol. 2003; 23: 1851–1856.
43. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr., Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention.; Am Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Association. Circulation. 2003; 107: 499–511.
44. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994–> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 1998; 47: 177–178.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  E. S. Brilakis, A. Khera, B. Saeed, S. Banerjee, D. K. McGuire, S. A. Murphy, and J. A. de Lemos Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings from the Dallas Heart Study Clin. Chem., December 1, 2008; 54(12): 1975 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Gardner, E. C. Reichert, M. K. Topham, and D. M. Stafforini Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein J. Biol. Chem., June 20, 2008; 283(25): 17099 - 17106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Daniels, G. A. Laughlin, M. J. Sarno, R. Bettencourt, R. L. Wolfert, and E. Barrett-Connor Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, M. M. Hoffmann, B. R. Winkelmann, I. Friedrich, G. Schafer, U. Seelhorst, B. Wellnitz, H. Wieland, B. O. Boehm, and W. Marz Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study) Clin. Chem., August 1, 2007; 53(8): 1440 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-D. Lee, D. R Jacobs Jr, P. J Schreiner, C. Iribarren, and A. Hankinson Abdominal obesity and coronary artery calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study Am. J. Clinical Nutrition, July 1, 2007; 86(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Garza, V. M. Montori, J. P. McConnell, V. K. Somers, I. J. Kullo, and F. Lopez-Jimenez Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review Mayo Clin. Proc., February 1, 2007; 82(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iribarren, A. S. Go, G. Husson, S. Sidney, J. M. Fair, T. Quertermous, M. A. Hlatky, and S. P. Fortmann Metabolic Syndrome and Early-Onset Coronary Artery Disease: Is the Whole Greater Than Its Parts? J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1800 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Jenny Lipoprotein-associated phospholipase A2: novel biomarker and causal mediator of atherosclerosis? Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2417 - 2418. [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O'Donoghue, D. A. Morrow, M. S. Sabatine, S. A. Murphy, C. H. McCabe, C. P. Cannon, and E. Braunwald Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial Circulation, April 11, 2006; 113(14): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kardys, H.-H. S. Oei, I. M. van der Meer, A. Hofman, M. M.B. Breteler, and J. C.M. Witteman Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary Atherosclerosis: The Rotterdam Study Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 631 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iribarren Lipoprotein-Associated Phospholipase A2 and Cardiovascular Risk: State of the Evidence and Future Directions Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
I. Gazi, E. S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A. D. Tselepis Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma Clin. Chem., December 1, 2005; 51(12): 2264 - 2273. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||